Stock Insights on Orexigen Therapeutics, Inc. (NASDAQ:OREX)

Orexigen Therapeutics, Inc. (NASDAQ:OREX) (TREND ANALYSIS) shares were traded with thin volume. The stock closed last trading session at $5.82, down by -3.64%, with a volume of 2,193,011 shares against an average volume for the last 3 months of 2,361,490.

Stock Performance: Click here for a free comprehensive Trend Analysis Report

OREX is expected to report quarter earnings on February 25. The Biotechnology company’s earning per share consensus Street estimate stands at $0.03.

Orexigen Therapeutics, Inc. (NASDAQ:OREX) is currently trading 25.58% below its 52-week-high, 87.14% above its 52-week-low. The 1-year range for the stock is $3.11 – $7.82. The stock price has underperformed the Nasdaq by 9.1%. OREX is currently valued at $0.72 billion and closed the last trading session at $5.82. The stock has a 50-day moving average of $5.51 and a 200-day moving average of $5.25.

Orexigen Therapeutics, Inc. (OREX) current short interest stands at 37.71 millions shares. It has increased by 2% from the same period of last month. Around 33% of the company’s shares, which are float, are short sold. With a 10-days average volume of 1.64 millions shares, the number of days required to cover the short positions stand at 23.1 days.

Is this a Buying Opportunity? Click here for a free Trend Analysis Report

There are currently eight analysts that cover OREX. Of those eight, eight have a Buy rating, . On a consensus basis this yields to a Buy rating. The consensus target price stands at $10.71.

A recent analyst activity consisted of RBC Capital Mkts who initiated their coverage on the stock with a Outperform rating on January 23. RBC Capital Mkts fixed their price target at $10. This corresponds to a 71.82% upside from the last closing price. On the date of report, the stock closed at $5.41.

Company profile

Orexigen Therapeutics Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of the central nervous system (CNS) disorders with an initial focus on obesity.

Related Posts

About The Author